RNA sequencing analysis revealed the induction of CCL3 expression in human intracranial aneurysms.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 07 2019
Historique:
received: 04 12 2018
accepted: 08 07 2019
entrez: 19 7 2019
pubmed: 19 7 2019
medline: 6 11 2020
Statut: epublish

Résumé

Intracranial aneurysm (IA) is a socially important disease as a major cause of subarachnoid hemorrhage. Recent experimental studies mainly using animal models have revealed a crucial role of macrophage-mediated chronic inflammatory responses in its pathogenesis. However, as findings from comprehensive analysis of unruptured human IAs are limited, factors regulating progression and rupture of IAs in humans remain unclear. Using surgically dissected human unruptured IA lesions and control arterial walls, gene expression profiles were obtained by RNA sequence analysis. RNA sequencing analysis was done with read count about 60~100 million which yielded 6~10 billion bases per sample. 79 over-expressed and 329 under-expressed genes in IA lesions were identified. Through Gene Ontology analysis, 'chemokine activity', 'defense response' and 'extracellular region' were picked up as over-represented terms which included CCL3 and CCL4 in common. Among these genes, quantitative RT-PCR analysis using another set of samples reproduced the above result. Finally, increase of CCL3 protein compared with that in control arterial walls was clarified in IA lesions. Findings of the present study again highlight importance of macrophage recruitment via CCL3 in the pathogenesis of IA progression.

Identifiants

pubmed: 31316152
doi: 10.1038/s41598-019-46886-2
pii: 10.1038/s41598-019-46886-2
pmc: PMC6637171
doi:

Substances chimiques

CCL3 protein, human 0
Chemokine CCL3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10387

Références

Acta Neurochir Suppl. 2015;120:13-5
pubmed: 25366592
N Engl J Med. 2012 Jun 28;366(26):2474-82
pubmed: 22738097
Stroke. 2004 Oct;35(10):2287-93
pubmed: 15322297
No Shinkei Geka. 2018 Apr;46(4):275-294
pubmed: 29686161
Neurosurgery. 2006 Nov;59(5):1069-76; discussion 1076-7
pubmed: 17016232
J Biol Regul Homeost Agents. 2010 Apr-Jun;24(2):185-95
pubmed: 20487632
Stroke. 2011 Jan;42(1):173-8
pubmed: 21106959
Neuroscience. 2012 Jan 10;201:105-13
pubmed: 22079572
J Immunol. 2011 Feb 15;186(4):2482-94
pubmed: 21220697
Acta Neuropathol. 2012 Jun;123(6):773-86
pubmed: 22249619
World Neurosurg. 2014 Dec;82(6):1127-30
pubmed: 23548847
Circulation. 2014 Jan 21;129(3):373-82
pubmed: 24446407
Stroke. 2001 Feb;32(2):485-91
pubmed: 11157187
BMC Bioinformatics. 2014 May 16;15:144
pubmed: 24884663
Acta Neuropathol Commun. 2013 Oct 28;1:71
pubmed: 24252658
Neurosurgery. 1999 Nov;45(5):1137-46; discussion 1146-7
pubmed: 10549930
Lancet Neurol. 2014 Jan;13(1):59-66
pubmed: 24290159
Eur Neurol. 2009;62(6):330-7
pubmed: 19752560
Stroke. 2009 Mar;40(3):942-51
pubmed: 19164781
Sci Signal. 2017 Feb 07;10(465):
pubmed: 28174280
Ann Med. 2014 Dec;46(8):597-606
pubmed: 25117779
Cerebrovasc Dis. 2012;34(2):121-9
pubmed: 22965244
Stroke. 2011 Nov;42(11):3156-62
pubmed: 21980208
Neurosurg Rev. 2015 Jul;38(3):531-40; discussion 540
pubmed: 25860660
Expert Opin Ther Targets. 2010 Mar;14(3):265-73
pubmed: 20128708
Lancet. 2007 Jan 27;369(9558):306-18
pubmed: 17258671
AJNR Am J Neuroradiol. 2011 Jan;32(1):20-5
pubmed: 21071538
J Stroke Cerebrovasc Dis. 2014 Feb;23(2):343-8
pubmed: 23697760
Oncotarget. 2017 Sep 28;8(62):104704-104705
pubmed: 29285206
Neuroscience. 2008 Jul 17;154(4):1398-407
pubmed: 18538937
Stroke. 2010 Feb;41(2):224-31
pubmed: 20044533
Stroke. 2009 Apr;40(4):1252-61
pubmed: 19228845

Auteurs

Tomohiro Aoki (T)

Innovation Center for Immunoregulation Technologies and Drugs (AK project), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan. tomoaoki@ncvc.go.jp.
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Osaka, 565-8565, Japan. tomoaoki@ncvc.go.jp.
Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan. tomoaoki@ncvc.go.jp.

Hirokazu Koseki (H)

Innovation Center for Immunoregulation Technologies and Drugs (AK project), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Osaka, 565-8565, Japan.
Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, 116-8567, Japan.

Haruka Miyata (H)

Innovation Center for Immunoregulation Technologies and Drugs (AK project), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Osaka, 565-8565, Japan.
Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Department of Neurosurgery, Shiga University of Medical Science, Shiga, 520-2192, Japan.

Masayoshi Itoh (M)

RIKEN Preventive Medicine and Innovation Program, Saitama, 351-0198, Japan.

Hideya Kawaji (H)

RIKEN Preventive Medicine and Innovation Program, Saitama, 351-0198, Japan.

Katsumi Takizawa (K)

Department of Neurosurgery, Japanese Red Cross Asahikawa Hospital, Hokkaido, 070-8530, Japan.

Akitsugu Kawashima (A)

Department of Neurosurgery, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, 276-8524, Japan.

Hiroshi Ujiie (H)

Department of Neurosurgery, Tokyo Rosai Hospital, Tokyo, 143-0013, Japan.

Takashi Higa (T)

Department of Neurosurgery, Tokyo Rosai Hospital, Tokyo, 143-0013, Japan.

Kenzo Minamimura (K)

Department of Neurosurgery, Shinkawahashi Hospital, Kanagawa, 210-0013, Japan.

Toshikazu Kimura (T)

Department of Neurosurgery, NTT Medical Center Tokyo, Tokyo, 141-8625, Japan.
Department of Neurosurgery, Japanese Red Cross Medical Center, Tokyo, 150-8935, Japan.

Hidetoshi Kasuya (H)

Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, 116-8567, Japan.

Kazuhiko Nozaki (K)

Department of Neurosurgery, Shiga University of Medical Science, Shiga, 520-2192, Japan.

Akio Morita (A)

Department of Neurosurgery, NTT Medical Center Tokyo, Tokyo, 141-8625, Japan.
Department of Neurological Surgery, Nippon Medical School, Tokyo, 113-8603, Japan.

Hirotoshi Sano (H)

Department of Neurosurgery, Shinkawahashi Hospital, Kanagawa, 210-0013, Japan.

Shuh Narumiya (S)

Innovation Center for Immunoregulation Technologies and Drugs (AK project), Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH